These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 1447905)

  • 21. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
    Serajuddin AT; Ranadive SA; Mahoney EM
    J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
    Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
    Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
    Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Islam F; Watanabe Y; Hayaishi O
    Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
    Escobales N; Crespo MJ; Altieri PI; Furilla RA
    J Hypertens; 1996 Jan; 14(1):115-21. PubMed ID: 12013483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
    Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
    J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
    Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
    Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE; MacDonald JS
    Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
    Johnston TP; Palmer WK
    Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
    Illingworth DR; Bacon S
    Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; MacDonald JS
    Eur Heart J; 1992 Jul; 13 Suppl B():2-6. PubMed ID: 1644096
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.
    Pentikainen PJ; Saraheimo M; Schwartz JI; Amin RD; Schwartz MS; Brunner-Ferber F; Rogers JD
    J Clin Pharmacol; 1992 Feb; 32(2):136-40. PubMed ID: 1613123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
    Steinhagen-Thiessen E
    Cardiology; 1994; 85(3-4):244-54. PubMed ID: 7987882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.